By equipping CAR-T cells with the ability to block a key tumor-producing protein called VEGF, the researchers gave the engineered immune cells the power not only to attack cancer directly, but also to dismantle the tumor’s defenses and restore the immune system’s ability to fight back.

In preclinical studies using mouse models of glioblastoma and ovarian cancer, the armored CAR-T cells outperformed standard CAR-T cell therapy as well as CAR-T cells combined with systemic anti-VEGF antibodies, significantly reducing tumor growth and extending survival.